Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study

Heart Rhythm

Volumn 12, Issue 6, 2015, Pages 1162-1168

  Di Biase, Luigi ^a,b,c,d   Lakkireddy, Dhanujaya ^e   Trivedi, Chintan ^a   Deneke, Thomas ^f   Martinek, Martin ^g   Mohanty, Sanghamitra ^a   Mohanty, Prasant ^a   Prakash, Sameer ^h   Bai, Rong ^a   Reddy, Madhu ^e   Gianni, Carola ^a   Horton, Rodney ^a   Bailey, Shane ^a   Sigmund, Elisabeth ^g   Derndorfer, Michael ^g   Schade, Anja ^f   Mueller, Patrick ^f   Szoelloes, Atilla ^f   Sanchez, Javier ^a   Al Ahmad, Amin ^a   Hranitzky, Patrick ^a   Gallinghouse, G Joseph ^a   Hongo, Richard H ⁱ   Beheiry, Salwa ⁱ   Pürerfellner, Helmut ^g   Burkhardt, J David ^a   Natale, Andrea ^a,c,i,j,k,l   more..

^a TEXAS CARDIAC ARRHYTHMIA INSTITUTE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c The University of Texas at Austin   (United States)

^d UNIVERSITY OF FOGGIA   (Italy)

^e UNIVERSITY OF KANSAS HOSPITAL   (United States)

^f Herz und Gefäßklinik Bad Neustadt A D Saale   (Germany)

^g Elisabehinen University Teaching Hospital Linz   (Austria)

^h Fort Worth Texas College of Osteopathic Medicine   (United States)

ⁱ CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^j STANFORD UNIVERSITY   (United States)

^k CASE WESTERN RESERVE UNIVERSITY   (United States)

^l SCRIPPS CLINIC   (United States)

more..

Author keywords

Anticoagulant; Atrial fibrillation; Catheterablation; Silentthromboemboliclesion; Stroke; Warfarin

Indexed keywords

APIXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIFFUSION WEIGHTED IMAGING; DRUG SAFETY; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; GROIN HEMATOMA; HEART ATRIUM THROMBOSIS; HEART TAMPONADE; HEMATOMA; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINUS RHYTHM; THROMBOSIS PREVENTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; ADVERSE EFFECTS; CLINICAL TRIAL; FEASIBILITY STUDY; POSTOPERATIVE HEMORRHAGE; SAFETY;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DIFFUSION MAGNETIC RESONANCE IMAGING; FACTOR XA INHIBITORS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDONES; SAFETY; WARFARIN;

EID: 84930383050     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2015.02.028     Document Type: Article

References (33)

1. H. Calkins, K.H. Kuck, and R. Cappato Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society Heart Rhythm 9 2012 632 696 e21
2. J.F. Viles-Gonzalez, and D. Mehta Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation Curr Cardiol Rep 13 2011 38 42
3. S.R. Vazquez, S.A. Johnson, and M.T. Rondina Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation Thromb Res 126 2010 e69 e77
4. D.D. Spragg, D. Dalal, A. Cheema, D. Scherr, K. Chilukuri, A. Cheng, C.A. Henrikson, J.E. Marine, R.D. Berger, J. Dong, and H. Calkins Complications of catheter ablation for atrial fibrillation: incidence and predictors J Cardiovasc Electrophysiol 19 2008 627 631
5. R. Cappato, H. Calkins, S.A. Chen, W. Davies, Y. Iesaka, J. Kalman, Y.H. Kim, G. Klein, A. Natale, D. Packer, and A. Skanes Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation J Am Coll Cardiol 53 2009 1798 1803
6. D. Scherr, K. Sharma, D. Dalal, D. Spragg, K. Chilukuri, A. Cheng, J. Dong, C.A. Henrikson, S. Nazarian, R.D. Berger, H. Calkins, and J.E. Marine Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation J Cardiovasc Electrophysiol 20 2009 1357 1363
7. L. Di Biase, J.D. Burkhardt, and P. Mohanty Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio Circulation 121 2010 2550 2556
8. P. Santangeli, L. Di Biase, R. Horton, J.D. Burkhardt, J. Sanchez, A. Al-Ahmad, R. Hongo, S. Beheiry, R. Bai, P. Mohanty, W.R. Lewis, and A. Natale Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis Circ Arrhythm Electrophysiol 5 2012 302 311
9. L. Di Biase, J.D. Burkhardt, and P. Santangeli Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of Coumadin In Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial Circulation 129 2014 2638 2644
10. L. Di Biase, F. Gaita, and E. Toso Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study Heart Rhythm 11 2014 791 798
11. S.J. Connolly, M.D. Ezekowitz, S. Yusuf RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
12. M.R. Patel, K.W. Mahaffey, and J. Garg ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
13. C.B. Granger, J.H. Alexander, J.J. McMurray ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
14. R.P. Giugliano, C.T. Ruff, and E. Braunwald ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
15. T. Nagao, Y. Inden, and M. Shimano Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation Pacing Clin Electrophysiol 38 2015 155 163
16. B.M. Kaess, S. Ammar, T. Reents, R. Dillier, C. Lennerz, V. Semmler, C. Grebmer, F. Bourier, A. Buiatti, C. Kolb, I. Deisenhofer, and G. Hessling Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon Am J Cardiol 115 2015 47 51
17. L. Di Biase Safety and efficacy of novel oral anticoagulants in the setting of atrial fibrillation ablation: is it time to celebrate the "funeral" of warfarin? J Interv Card Electrophysiol 41 2014 103 105
18. D. Lakkireddy, Y.M. Reddy, and L. Di Biase Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J Am Coll Cardiol 59 2012 1168 1174
19. J.S. Kim, F. She, K. Jongnarangsin, and A. Chugh Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation Heart Rhythm 10 2013 483 489
20. M. Bassiouny, W. Saliba, and J. Rickard Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation Circ Arrhythm Electrophysiol 6 2013 460 466
21. P. Sardar, R. Nairooz, S. Chatterjee, J. Wetterslev, J. Ghosh, and W.S. Aronow Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation Am J Cardiol 11 2014 1173 1177
22. R. Providência, J.P. Albenque, S. Combes, A. Bouzeman, B. Casteigt, N. Combes, K. Narayanan, E. Marijon, and S. Boveda Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis Heart 100 2014 324 335
23. S.H. Hohnloser, and A.J. Camm Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature Europace 15 2013 1407 1411
24. M. Shurrab, C.A. Morillo, S. Schulman, N. Kansal, A. Danon, D. Newman, I. Lashevsky, J.S. Healey, and E. Crystal Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis Can J Cardiol 29 2013 1203 1210
25. D. Lakkireddy, Y.M. Reddy, and L. Di Biase Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J Am Coll Cardiol 63 2014 982 988
26. L. Di Biase, C.S. Elayi, and T.S. Fahmy Atrial fibrillation ablation strategies for paroxysmal patients: randomized comparison between different techniques Circ Arrhythm Electrophysiol 2 2009 113 119
27. L. Di Biase, P. Santangeli, and A. Natale How to ablate long-standing persistent atrial fibrillation? Curr Opin Cardiol 28 2013 26 35
28. D.M. Witt, T. Delate, N.P. Clark, D.A. Garcia, E.M. Hylek, W. Ageno, F. Dentali, and M.A. Crowther Nonadherence with INR monitoring and anticoagulant complications Thromb Res 132 2013 e124 e130
29. D. Snipelisky, C. Kauffman, K. Prussak, G. Johns, K. Venkatachalam, and F. Kusumoto A comparison of bleeding complications post-ablation between warfarin and dabigatran J Interv Card Electrophysiol 35 2012 29 33
30. B.A. Steinberg, V. Hasselblad, B.D. Atwater, T.D. Bahnson, J.B. Washam, J.H. Alexander, J.P. Daubert, and J.P. Piccini Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies J Interv Card Electrophysiol 37 2013 213 221
31. G.V. Naccarelli, R. Cappato, S.H. Hohnloser, F.E. Marchlinski, D.J. Wilber, J. Xiang, C. Ma, S. Hess, D.W. Davies, L.E. Fields, and A. Natale On behalf of the VENTURE-AF Investigators. Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation J Interv Card Electrophysiol 41 2014 107 116
32. L. Di Biase, and A. Natale Apixaban is dear to me, but dearer still is warfarin Pacing Clin Electrophysiol 38 2015 153 154
33. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579